K Pulaski

892 total citations
8 papers, 697 citations indexed

About

K Pulaski is a scholar working on Neurology, Endocrinology, Diabetes and Metabolism and Molecular Biology. According to data from OpenAlex, K Pulaski has authored 8 papers receiving a total of 697 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Neurology, 4 papers in Endocrinology, Diabetes and Metabolism and 2 papers in Molecular Biology. Recurrent topics in K Pulaski's work include Pituitary Gland Disorders and Treatments (4 papers), Neurofibromatosis and Schwannoma Cases (4 papers) and Growth Hormone and Insulin-like Growth Factors (3 papers). K Pulaski is often cited by papers focused on Pituitary Gland Disorders and Treatments (4 papers), Neurofibromatosis and Schwannoma Cases (4 papers) and Growth Hormone and Insulin-like Growth Factors (3 papers). K Pulaski collaborates with scholars based in United States, Spain and Germany. K Pulaski's co-authors include Lee B. Jacoby, Bernd R. Seizinger, M. MacCollin, R Eldridge, Vijaya Ramesh, James A. Trofatter, James F. Gusella, Muriel I. Kaiser‐Kupfer, Dilys M. Parry and H. Stacy Nicholson and has published in prestigious journals such as The Journal of Clinical Endocrinology & Metabolism, Human Molecular Genetics and Journal of neurosurgery.

In The Last Decade

K Pulaski

8 papers receiving 677 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
K Pulaski United States 8 395 287 239 147 104 8 697
P Mennonna Italy 15 312 0.8× 227 0.8× 75 0.3× 116 0.8× 108 1.0× 49 582
Toshiaki Sano Japan 12 182 0.5× 92 0.3× 153 0.6× 94 0.6× 127 1.2× 16 518
Patrice C. Abell-Aleff United States 10 207 0.5× 190 0.7× 105 0.4× 57 0.4× 121 1.2× 14 500
Eriks A. Lusis United States 12 277 0.7× 400 1.4× 113 0.5× 53 0.4× 171 1.6× 14 724
A. Maíllo Spain 17 457 1.2× 410 1.4× 92 0.4× 76 0.5× 206 2.0× 48 721
Kaoru Kurisu Japan 12 215 0.5× 216 0.8× 133 0.6× 48 0.3× 187 1.8× 38 580
Scheithauer Bw United States 15 238 0.6× 192 0.7× 372 1.6× 38 0.3× 175 1.7× 29 719
Ryszard Czepko Poland 11 198 0.5× 94 0.3× 128 0.5× 52 0.4× 117 1.1× 51 446
Stéphane Goutagny France 14 664 1.7× 628 2.2× 93 0.4× 101 0.7× 158 1.5× 34 930
Dan X. Cai United States 13 331 0.8× 313 1.1× 66 0.3× 69 0.5× 163 1.6× 17 743

Countries citing papers authored by K Pulaski

Since Specialization
Citations

This map shows the geographic impact of K Pulaski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K Pulaski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K Pulaski more than expected).

Fields of papers citing papers by K Pulaski

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K Pulaski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K Pulaski. The network helps show where K Pulaski may publish in the future.

Co-authorship network of co-authors of K Pulaski

This figure shows the co-authorship network connecting the top 25 collaborators of K Pulaski. A scholar is included among the top collaborators of K Pulaski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K Pulaski. K Pulaski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
Sesmilo, Gemma, Wesley P. Fairfield, Laurence Katznelson, et al.. (2002). Cardiovascular Risk Factors in Acromegaly before and after Normalization of Serum IGF-I Levels with the GH Antagonist Pegvisomant. The Journal of Clinical Endocrinology & Metabolism. 87(4). 1692–1699. 96 indexed citations
2.
Fairfield, Wesley P., Gemma Sesmilo, Laurence Katznelson, et al.. (2002). Effects of a growth hormone receptor antagonist on bone markers in acromegaly. Clinical Endocrinology. 57(3). 385–390. 30 indexed citations
3.
Katznelson, Laurence, David L. Kleinberg, Mary Lee Vance, et al.. (2001). Hypogonadism in patients with acromegaly: data from the multi‐centre acromegaly registry pilot study. Clinical Endocrinology. 54(2). 183–188. 61 indexed citations
4.
Parry, Dilys M., M. MacCollin, Muriel I. Kaiser‐Kupfer, et al.. (1996). Germ-line mutations in the neurofibromatosis 2 gene: correlations with disease severity and retinal abnormalities.. PubMed. 59(3). 529–39. 159 indexed citations
5.
Jacoby, Lee B., Trina Mohney, K Pulaski, et al.. (1994). Exon scanning for mutation of the NF2 gene in schwannomas. Human Molecular Genetics. 3(3). 413–419. 160 indexed citations
6.
MacCollin, M., Vijaya Ramesh, Lee B. Jacoby, et al.. (1994). Mutational analysis of patients with neurofibromatosis 2.. PubMed. 55(2). 314–20. 91 indexed citations
7.
Jacoby, Lee B., E. Tessa Hedley‐Whyte, K Pulaski, Bernd R. Seizinger, & Robert L. Martuza. (1990). Clonal origin of pituitary adenomas. Journal of neurosurgery. 73(5). 731–735. 81 indexed citations
8.
Jacoby, Lee B., et al.. (1990). Clonal analysis of human meningiomas and schwannomas.. PubMed. 50(21). 6783–6. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026